Manibiotech, I get the frustration, but let’s not misrepresent the situation. Northwest Biotherapeutics is in the final phase of regulatory review, what’s called the labeling phase. That means they’ve already completed the scientific assessment and received the committee opinion. What happens now is legal and procedural: negotiating the exact product label, prescribing language, and post-market conditions. At this stage, silence isn’t evasive, it’s mandatory.
This is exactly why the company doesn’t hold open Q&A calls. They’re not a commercial-stage biotech, and they’re under legal obligation to avoid forward-looking disclosures that could compromise the review. Anything said out loud, especially about timelines or scope, could be considered market-moving and trigger consequences from the MHRA or any other regulator they’re preparing to file with.
The idea that “you can’t ask questions to a PDF” might sound good in a comment thread, but it misses the point. Filings are where the legally reviewable facts live. That’s where institutions, regulators, and serious investors go to assess the real story, not speculation, not forum noise.
When someone tries to mock or minimize that process, especially right as the company reaches the edge of approval, it’s not about transparency. It’s about disrupting the people paying attention.
So if you have a real question, the trail is public. If not, the timing of this pushback says more than the content does.
Market Data 
Markets 
AI
